



ASX Release

3 October 2022

Receipt of R&D Tax Incentive Rebate

Melbourne, Australia; 3 October 2022

Acrux Limited (ASX:ACR) is pleased to announce receipt of \$2,293,418.53 from the Australian Tax Office in relation to its R&D Tax Incentive Rebate for the 2021/2022 financial year for a second subsidiary company. A total of \$3,276,840.42 has now been received across the Company, which is the full claimed amount in relation to eligible Research and Development expenditure incurred in Australia.

Additionally, AusIndustry has favourably assessed our application for an Overseas Finding and has determined certain expenditure in relation to overseas activities conducted through this period to be eligible for the R&D Tax Incentive Rebate. An additional claim will be made for these eligible overseas activities and accordingly further funds are expected to be received within this program over the coming months.

The R&D Tax Incentive is an Australian Government program under which eligible companies receive cash refunds for research and development expenditure.

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

Michael Kotsanis

Acrux Limited

CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Drawing on 25 years of experience and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au